

**NICHOLAS REBOLD**  
**PharmD, MPH, BCIDP, AAHIVP**

Email: [Nicholas.rebold@howard.edu](mailto:Nicholas.rebold@howard.edu) • Phone: 202-806-4208

**EDUCATION**

---

Master of Public Health	August 2020 – August 2022
• Wayne State University (WSU)	
Doctor of Pharmacy	August 2014 – May 2018
• Virginia Commonwealth University (VCU) School of Pharmacy	
Bachelor of Arts in Biology, Government Minor	August 2010 – May 2014
• University of Virginia (UVA)	

**PROFESSIONAL EXPERIENCE**

---

Assistant Professor – Probationary Tenure-Track	July 2024 – Present
• Howard University – Department of Clinical & Administrative Pharmacy Sciences	
Clinical Assistant Professor	August 2022 – July 2024
• Howard University – Department of Clinical & Administrative Pharmacy Sciences	
Clinical Infectious Diseases Pharmacist	August 2022 – Present
• Howard University Hospital – Department of Pharmacy	
Staff Pharmacist (Weekday evenings/weekends)	August 2018 – July 2020
• Boston Medical Center	
Pharmacy VA Learning Opportunities Residency (VALOR) Intern	June 2016 – May 2017
• Hunter Holmes McGuire VA Medical Center	
Pharmacy Intern	May 2015 – May 2016
• CVS Pharmacy; Warrenton, Virginia and Richmond, Virginia	
Pharmacy Volunteer	September 2013 – May 2014
• Madison House Volunteering; University of Virginia Hospital	

**POST-GRADUATE TRAINING**

---

Infectious Diseases Outcome Research Fellowship	July 2020 – August 2022
• Anti-Infective Research Lab - Eugene Applebaum College of Pharmacy and Health Sciences (EACPHS) – Director: Michael Rybak, PharmD, MPH, PhD	
PGY-2 Infectious Diseases Pharmacy Resident	July 2019 – July 2020
• Boston Medical Center – Director: Karrine Brade, PharmD, BCPS, BCIDP	
PGY-1 Pharmacy Resident	June 2018 – June 2019
• Boston Medical Center – Director: Jason Mordino, PharmD, BCCCP	

**TEACHING EXPERIENCES**

---

Course Coordinator: IT Lab II – 2 credits (48 hrs)	2023 – Present
• HUCOP CLPS (20052-372): Integrated Therapeutics Lab II – P2 Spring (144 hrs cumulative)	
Course Co-Coordinator: IT3 (Antimicrobials & Infectious Diseases) – 4 credits (36 hrs)	2023 – Present
• HUCOP CLPS (20054-370): Integrated Therapeutics 3 – P2 Spring (88 hrs cumulative)	
• HUCOP CLPS (52456-370-05): Integrated Therapeutics 3 – P2/3 Summer (20 hrs cumulative)	
Lecturer: IT1 (Intro to Therapeutics) – 3 credits (4 hrs)	2023 – Present
• HUCOP CLPS (80038-425): Foundations of Integrated Therapeutics – P2 Fall (14 hrs cumulative)	
Lecturer: PPR2 (Professional Practice Readiness) – 2 credits (8 hrs)	2023 – Present
• HUCOP CLPS (320-01): PPR2 – P3 Spring (24 hrs cumulative)	
Lecturer: IT4 (Bone, Joint, Immunology) – 2 credits (4 hrs)	2023 – 2025
• HUCOP CLPS (371-01): Integrated Therapeutics 4 – P2 Spring (12 hrs cumulative)	
Didactic Lecture: PK/PD (Part III) and Bone and Joint Infections (6 hrs)	February 2022

- PHA 5215: Principles of Pharmacotherapy IV: Infectious Diseases – EACPHS  
Didactic Lecture: PK/PD (Part III) and Bone and Joint Infections (6 hrs) February-March 2021
- PHA 5215: Principles of Pharmacotherapy IV: Infectious Diseases – EACPHS  
Small Group Facilitation: Oral Pharmacotherapy cases (12 hrs) January 2021
- PPS V: Foundations Recitation - EACPHS  
Didactic Lecture: Opportunistic Infections (2 hrs) November 2019
- Clinical Disease Management 3 – Northeastern University School of Pharmacy  
Didactic Lecture: Drugs, Bugs, and Stewardship (1 hr) September 2019
- Physician Assistant Antibiotic Review Lecture  
Small Group Facilitation: Complications of Diabetes (4 hrs) November 2017
- PHAR 541: Patient Assessment in Pharmacy – VCU School of Pharmacy  
Small Group Facilitation: Chemotherapy Preparation (8 hrs) November 2017
- PHAR 640: Foundations V – VCU School of Pharmacy  
Counseling: Ophthalmic Prescriptions (4 hrs) November 2017
- PHAR 523: Foundations I – VCU School of Pharmacy  
Counseling: Respiratory Devices (8 hrs) & Case Development: Chronic Asthma (2 hrs) November 2017
- PHAR 534: Foundations III – VCU School of Pharmacy

### **PHARMACY RESIDENCY PRACTICE EXPERIENCES**

---

#### PGY2

ID Consult Advanced	May 2020 – June 2020
COVID-ID/Staffing	April 2020 – May 2020
ID Research	March 2020 – April 2020
Infectious Diseases - Medicine	January 2020 – March 2020
Surgical Intensive Care Unit	December 2019 – January 2020
ID Consult	November 2019 – December 2019
Antimicrobial Stewardship	October 2019 – November 2019
HIV Clinic	September 2019 – October 2019
Introduction to ID – Microbiology Laboratory	July 2019 – August 2019
Internal Medicine: Transitions of Care	June 2019 – July 2019

#### PGY1

Practice Management	May 2019 – June 2019
Ambulatory Care: GI/HCV Clinic / Family Medicine Clinic	April 2019 – May 2019
Medical Intensive Care Unit	March 2019 – April 2019
Surgery Floor	January 2019 – March 2019
Emergency Medicine	December 2018 – January 2019
Infectious Disease	November 2018 – December 2018
Ambulatory Care: HIV Clinic / Family Medicine Clinic	October 2018 – November 2018
Internal Medicine II: Renal	September 2018 – October 2018
Internal Medicine I: General Medicine	July 2018 – August 2018

### **ADVANCED PHARMACY PRACTICE EXPERIENCES**

---

Ambulatory Care – Navajo Area Indian Health Service (IHS)	March 2018 – April 2018
Advanced Hospital – Fauquier Health	February 2018 – March 2018
Academic Teaching – Elective – VCU School of Pharmacy	November 2017 – December 2017
Acute Care II – Pediatric Oncology – VCU Health System	October 2017 – November 2017
Geriatrics – Fauquier Health	August 2017 – September 2017
Internal Medicine – Elective – Salem VA Medical Center	July 2017 – August 2017
Advanced Community – Walgreens Pharmacy	June 2017 – July 2017
Acute Care I – General Medicine – Fauquier Health	May 2017 – June 2017

## INTRODUCTORY PHARMACY PRACTICE EXPERIENCES

Hospital Pharmacy – Fauquier Health  
Community Pharmacy – Harris Teeter

April 2016 – May 2016  
May 2015

## PUBLICATIONS

1. Caniff KE, **Rebold N**, Richards N, et al. Optimizing discharge antibiotic prescribing: A multicenter evaluation of pharmacist-led interventions in community hospitals. *Am J Health Syst Pharm*. Published online February 13, 2026:zxag051. doi:[10.1093/ajhp/zxag051](https://doi.org/10.1093/ajhp/zxag051)
2. Moore J, IHEME N, **Rebold NS**, Kusi H, Mere C, Nwaogwugwu U, Ettienne E, Chaijamorn W, Rung D. Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence. *Pharmacy*. 2025;13(2):46. doi:[10.3390/pharmacy13020046](https://doi.org/10.3390/pharmacy13020046)
3. Caniff KE, **Rebold N**, Xhemali X, et al. Real-World Applications of Imipenem/Cilastatin/Relebactam: Insights from a Multicenter Observational Cohort Study. *Open Forum Infectious Diseases*. Published online February 26, 2025:ofaf112. doi:[10.1093/ofid/ofaf112](https://doi.org/10.1093/ofid/ofaf112)
4. **Rebold N**, Alosaimy S, Pearson JC, Dionne B, Taqi A, Lagnf AM, Lucas K, Biagi M, Lombardo N, Eudy J, Anderson DT, Mahoney MV, Kufel WD, D'Antonio JA, Jones BM, Frens JJ, Baumeister T, Geriak M, Sakoulas G, Farmakiotis D, Delaportas D, Larew J, Veve MP, Rybak MJ. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study. *Infect Dis Ther* 13, 565–579 (2024). <https://doi.org/10.1007/s40121-024-00933-2>
5. Holger DJ, Althubyani A, Morrisette T, **Rebold N**, Tailor M. Updates in pulmonary drug-resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLM. *Pharmacotherapy*. 2024; 44: 268-282. doi:[10.1002/phar.2909](https://doi.org/10.1002/phar.2909)
6. Caniff KE, **Rebold N**, Rybak MJ. Oral stepdown in Gram positive bloodstream infections: A step in the right direction. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 2023;43(3):247-256. doi:[10.1002/phar.2775](https://doi.org/10.1002/phar.2775)
7. Kunz Coyne AJ, El Ghali A, Lucas K, Witucki P, **Rebold N**, Holger DJ, Veve MP, Rybak MJ. High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC  $\beta$ -lactamase Production. *Open Forum Infectious Diseases*. 2023;10(3):ofad034. doi:[10.1093/ofid/ofad034](https://doi.org/10.1093/ofid/ofad034)
8. **Rebold N**, Lagnf AM, Alosaimy S, Holger DJ, Witucki P, Mannino A, Dierker M, Lucas K, Kunz Coyne AJ, El Ghali A, Caniff KE, Veve MP, Rybak MJ. Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure. *Microbiology Spectrum*. 2023;11(1):e02647-22. doi:[10.1128/spectrum.02647-22](https://doi.org/10.1128/spectrum.02647-22)
9. Hemenway A, **Rebold N**. The Role of Rifampin in Bone and Joint Infections. *Contagion Live*. Published September 7, 2022. <https://www.contagionlive.com/view/the-role-of-rifampin-in-bone-and-joint-infections>
10. Holger DJ, **Rebold NS**, Alosaimy S, et al. Impact of Ceftolozane–Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas aeruginosa* Lower Respiratory Tract Infections. *Infect Dis Ther*. Published online September 1, 2022. doi:[10.1007/s40121-022-00687-9](https://doi.org/10.1007/s40121-022-00687-9)
11. **Rebold N**, Lodise T, Rybak MJ. Panacea or oversimplification: Relating AUC and troughs. *Am J Health-Syst Pharm*. 2022;79(12):1019-1021. doi:[10.1093/ajhp/zxac031](https://doi.org/10.1093/ajhp/zxac031)
12. **Rebold N**, Alosaimy S, Morrisette T, Holger D, Lagnf AM, Ansari I, Belza AC, Cheaney L, Hussain H, Herbin SR, Abdul-Mutakabbir J, Carron C, Sandhu A, Chopra T, Rybak MJ. Clinical characteristics

associated with positive blood culture and bacterial bloodstream coinfection in COVID-19. *Infect Dis Ther*. Published May 2022.

13. Kunz Coyne AJ, El Ghali A, Holger D, **Rebold N**, Rybak MJ. Therapeutic Strategies for Emerging Multidrug-Resistant *Pseudomonas aeruginosa*. *Infect Dis Ther*. Published online Feb 2022. doi:[10.1007/s40121-022-00591-2](https://doi.org/10.1007/s40121-022-00591-2)
14. **Rebold N**, Morrisette T, Lagnf AM, Alosaimy S, Holger D, Barber K, Justo JA, Antosz K, Carlson TJ, Frens JJ, Biagi M, Kufel WD, Moore WJ, Mercurio N, Raux BR, Rybak MJ. Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. *Open Forum Infectious Diseases*. 2021;8(12):ofab554. doi:[10.1093/ofid/ofab554](https://doi.org/10.1093/ofid/ofab554)
15. Alosaimy S, Lagnf AM, Morrisette T, [...] **Rebold N**, et al. Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant *Staphylococcus aureus* Bacteremia: STAPH Study. *Open Forum Infect Dis*. 2021;8(7):ofab261.
16. **Rebold N**, Holger D, Alosaimy S, Morrisette T, Rybak M. COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. *Infect Dis Ther*. 2021;10(1):93-113.
17. **Rebold N**, Holger D, Rybak M. Vancomycin Dosing Guidelines: Where Do We Go From Here? *Pharmacy Practice News*. Special Edition: December 2020.
18. **Rebold N** and Holger D. COVID-19: Review of Treatment Options. MAD-ID Newsletter: Spring 2020;10(1):3-17.
19. **Rebold N**. Seeing the difficulties of Treating *Clostridium difficile* Infection: Review of Diagnostic and Treatment Options. *INPHARMATION*. 2017;2(3):5-9.

## **PEER REVIEW**

### Independent Peer Review

<i>Journal of Antimicrobial Chemotherapy</i>	December 2025 – Present
• One manuscript reviewed	
<i>Expert Review of Anti-Infective Therapy</i>	November 2025 – Present
• One manuscript reviewed	
<i>Drugs</i>	October 2024 – Present
• One manuscript reviewed	
<i>BMC Infectious Diseases</i>	September 2024 – Present
• One manuscript reviewed	
<i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i>	April 2024 – Present
• One manuscript reviewed	
<i>Open Forum Infectious Diseases</i>	March 2024 – Present
• Four manuscripts reviewed	
<i>Clinical Infectious Diseases</i>	October 2022 – Present
• Four manuscripts reviewed	
<i>BMJ Open Respiratory Research</i>	September 2021 – Present
• One manuscript reviewed	
<i>Pharmacotherapy</i>	September 2020 – Present
• Thirteen manuscripts reviewed	
<i>American Journal of Health-System Pharmacy</i>	July 2021 – Present
• Seven manuscripts reviewed	

### Mentored Peer Review

<i>Journal of Antimicrobial Chemotherapy</i>	March 2021 – July 2022
• One manuscript reviewed	
<i>Open Forum Infectious Diseases</i>	March 2021 – July 2022
• One manuscript reviewed	
<i>Clinical Infectious Diseases</i>	August 2020 – July 2022
• Two manuscripts reviewed	

- One manuscript reviewed

## GRANTSMANSHIP

---

1. Rungkitwattanakul D, **Rebold N**, Ofoegbu A, Mere C, Nwaugwugwu U. Leveraging Clinical Decision Support and Kidney Stress Biomarkers to Prevent Hospital-Acquired Acute Kidney Injury in High-Risk Populations. June 2025. ASHP Foundation Optimizing Technology Solutions Innovation Grant. PI: Rung, D. Role: Co-investigator.
2. **Rebold N**, Holger D, El Ghali A, Veve M, Davis SL, Rybak MJ. Pharmacist Review of Antibiotics for Discharge. December 2021. Michigan Department of Health and Human Services. PI: Rybak, MJ. Role: Co-investigator.
3. **Rebold N**, Rybak MJ. Evaluating the Impact of Combination Therapy in Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis. September 2021. AHA Postdoctoral Fellowship. PI: **Rebold N**. Sponsor: Rybak, MJ.
4. **Rebold N**, Alosaimy S, Morrisette T, Holger D, Lagnf AM, Rybak MJ. Ceftazidime-Avibactam Contemporary Use at Academic Hospital Systems. July 2021. PI: Rybak MJ. Role: Co-investigator.
5. **Rebold N**, Alosaimy S, Holger D, Morrisette T, Rybak MJ. Cefiderocol for Multidrug-Resistant Non-Lactose Fermenting Gram-Negative Bacteria: A multi-center retrospective study. June 2021. PI: Rybak MJ. Role: Co-investigator.
6. **Rebold N**, Alosaimy S, Morrisette T, Lagnf AM, Rybak MJ. Real-World Experience with Dalbavancin versus Standard-of-Care for Invasive Bloodstream Infections. April 2021. PI: Rybak MJ. Role: Co-investigator.
7. **Rebold N**, Alosaimy S, Morrisette T, Holger D, Scipione M, Zhao JJ, Yost R, Mariani M, Murray KP, Rybak MJ. A comparison of two methods of AUC-targeted estimation for vancomycin dosing in an academic medical center: A prospective cohort study between first-order pharmacokinetic AUC estimation and Bayesian AUC estimation. October 2020. PI: Rybak MJ. Role: Co-investigator.

## PROFESSIONAL PRACTICE

---

- Preceptor: ID Consult – Experiential rotation at Howard University Hospital. February 2023 – Present
- Pharmacy Residents: 10; Pharmacy Students: 31.
- HUH Guidelines: HIV-ART, formulary, and protocol. April 2023
- Microscan system breakpoints update and implementation. November 2022 – Present
- HUH Guidelines: COVID-19 Therapies. November 2022
- BioFire Blood-culture Identification 2 (BCID2) panel system implementation. October 2022 – Present
- Vancomycin AUC/MIC dosing, guidelines, protocol, and implementation. October 2022 – February 2023
- Improving antibiotic prescribing upon hospital discharge: A transitions-of-care (TOC) focused, antimicrobial stewardship initiative July 2019 – May 2020
- ACCP 2020 Virtual Poster Symposium; Vizient 2019 Poster Symposium; ECCMID 2020
- Pharmacist-led efforts to achieve UNAIDS 90-90-90 Targets at BMC July 2018 – May 2019
- Vizient 2018 Poster Session; MSHP Annual 2019; Eastern States Conference 2019
- Fecal Microbiota Transplant (FMT) Capsules Drug Monograph September 2018
- Medication Use Evaluation of Voriconazole Dosing October 2017 – November 2017
- Evaluation of a multimodal pain protocol versus a traditional opioid based protocol in total joint replacement (TJR) June 2017 – December 2017
- ASHP Midyear 2017 Poster Presentation
- Medication Use Evaluation of Post-Surgical VTE Prophylaxis December 2016 – April 2017

## PROFESSIONAL DEVELOPMENT

---

### Journal Clubs

Moderator. ACCP ID-PRN Learner-led Journal Club. May 2026  
 Moderator. ACCP ID-PRN Learner-led Journal Club. April 2023  
 Moderator. ACCP ID-PRN Learner-led Journal Club. February 2023

### Podium Presentations

“The ART of Standardization: Impact of a Pharmacist-Led Antiretroviral Formulary Protocol on HIV management”. 2026 NPhA Annual Convention. August 2026

- Pending. ACPE board-accredited 1.0 CE. Presented to pharmacists.

“Opportunistic Infections in Persons with HIV”. MAAETC. April 2026

- ACPE board-accredited 1.0 CE. Presented to pharmacists, physicians, nurses.

“Guideline and Antibiotic Updates in Urinary Tract Infections”. HUPAA General Meeting. March 2026

- ACPE board-accredited 1.0 CE. Presented to pharmacists.

“HIV & Immunizations”. MAAETC Clinical Scholars Program. March 2026

- ACPE board-accredited 1.0 CE. Presented to pharmacists, physicians, nurses.

“Opportunistic Infections Training”. MAAETC Clinical Preceptorship. March 2025

- ACPE, CME, CNE board-accredited 1.0 CE. Presented to pharmacists, physicians, nurses.

“HIV/AIDs & Opportunistic Infection”. DC License 2025 Renewal CE Program. February 2025

- ACPE board-accredited 1.0 CE. Presented to pharmacists.

“HIV and AIDS-related Opportunistic Infections: Updates for Clinical Practice”. MAAETC. May 2024

- ACPE, CME, CNE board-accredited 1.0 CE. Presented to pharmacists, physicians, nurses.

“HIV/AIDs & Opportunistic Infection”. DC License 2023 Renewal CE Program. February 2023

- ACPE board-accredited 1.0 CE. Presented to pharmacists.

“HIV and AIDS-related Opportunistic Infections: Updates for Clinical Practice”. MAAETC. Dec 2022

- ACPE board-accredited 1.0 CE. Presented to pharmacists, physicians, nurses.

“Special Pops: A Slew of ‘Stew: Antibiotic Stewardship in Special Populations” December 2019

- ACPE board-accredited 1.0 CE. Presented to pharmacists, residents, and pharmacy students.

“Short and Treat: Optimizing Antibiotic Therapy Durations” March 2019

- ACPE board-accredited 1.0 CE. Presented to pharmacists, residents, and pharmacy students.

“Sexually Transmitted Diseases: 2017 Surveillance Report, Resistance Management, and Treatment” October 2018

- ACPE board-accredited 1.0 CE. Presented to pharmacists, residents, and pharmacy students.

### Poster Presentations

1. Davis S, Krah J, Mears A, **Rebold N**, Rungkitwattanakul J. Linezolid/Daptomycin for Gram-Positive Infection Treatment May Improve Kidney Related Outcomes Compared With Vancomycin Among High-Risk African American Patients. Las Vegas, NV. December 2025. ASHP Midyear Clinical Meeting & Exhibition 2025.
2. Turnquest TA, Krah J, **Rebold N**, Rungkitwattanakul J. Clinical Impact of Genetic Testing on Kidney Disease Management: Implications for Pharmacotherapy. Las Vegas, NV. December 2025. ASHP Midyear Clinical Meeting & Exhibition 2025.
3. Chang S, Tolla G G, Lyons A, **Rebold N**. Optimizing Fungal Identification and Susceptibilities to Improve Outcomes at Howard University Hospital. Hershey, PA. May 2025. Eastern States Residency Conference 2025.
4. Chang S, Tolla G G, Lyons A, **Rebold N**. Optimizing Fungal Identification and Susceptibilities to Improve Patient Outcomes at Howard University Hospital. New Orleans, LA. December 2024. 2024 ASHP Midyear Clinical Meeting & Exhibition.
5. Brooks M, Gajjala J, **Rebold N**. Adjunctive use of Clindamycin in the Treatment of Pulmonary and Skin Infections among Intensive Care Unit (ICU) Patients. Anaheim, CA. December 2023. 2023 ASHP Midyear Clinical Meeting & Exhibition.

6. Ukpokpo E, Rubio A, Daftary M, Gasmelseed H, Mahgoub S, **Rebold N**. Impact of a standardized protocol to optimize inpatient antiretroviral therapy conversions: A retrospective observational cohort study. Anaheim, CA. December 2023. 2023 ASHP Midyear Clinical Meeting & Exhibition.
7. Patterson K, Nworji A, Rungkitwattanakul D, **Rebold N**. Performance of BioFire Blood Culture Identification 2 Panel (BCID2) in Adult Patients with Bloodstream Infection: A single center experience. Anaheim, CA. December 2023. 2023 ASHP Midyear Clinical Meeting & Exhibition.
8. **Rebold N**, Guo Y, Chang M, Carlson TJ, Frens JJ, Barber K, Kufel WD, Justo JA, Antosz K, Biagi M, Moore WJ, Raux BR, Rybak MJ. *Pseudomonas aeruginosa* infections treated with imipenem-cilastatin-relebactam. June 2022. ASM Microbe 2022.
9. **Rebold N**, Lagnf AM, Savickas D, Yost C, Belza AC, Blackman AL, Brade KD, Alosaimy S, Witucki P, Rybak MJ. Multicenter study of trimethoprim/sulfamethoxazole versus linezolid oral step-down therapy for methicillin-resistant *Staphylococcus aureus* bloodstream infections. May 2022. 24<sup>th</sup> Annual Making a Difference in Infectious Diseases (MAD-ID) Meeting.
10. **Rebold N**, Alosaimy S, Holger D, Lucas K, Guo Y, Chang M, Biagi M, Carlson TJ, Frens JJ, Barber K, Justo JA, Hayes J, Carr A, Kufel WD, Moore WJ, Zeitler K, Morrisette T, Rybak MJ. Factors associated with clinical success in treatment with imipenem-cilastatin-relebactam. Late-breaker. April 2022. 32<sup>nd</sup> European Congress of Clinical Microbiology & Infectious Diseases.
11. **Rebold N**, Barber K, Justo JA, Antosz K, Carlson TJ, Biagi M, Kufel WD, Mercurio N, Raux BR, Morrisette T, Lagnf AM, Alosaimy S, Holger D, Rybak MJ. Early Multicenter Experience with Imipenem-Cilastatin-Relebactam for Gram-Negative Infections. October 2021. ACCP 2021 Annual Meeting.
12. Holger D, Lagnf AM, Belza AC, Alosaimy S, **Rebold N**, Morrisette T, Veve MP, Rybak MJ. Real World, Multicenter Evaluation of T2Candida Panel in Patients with Candidemia. October 2021. ACCP 2021 Annual Meeting.
13. Alosaimy S, [...] **Rebold N**, et al. Identification of eravacycline place in therapy using a real-world multi-center database analysis. October 2021. ACCP 2021 Annual Meeting.
14. **Rebold N**, Alosaimy S, Lagnf AM, Holger D, Rybak MJ. Comparing Treatments of Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis by People Who Inject Drugs. September 2021. IDWeek 2021 Virtual Meeting.
15. Alosaimy S, Morrisette T, [...] **Rebold N**, et al. Predictors for Clinical Success in Patients Treated with Eravacycline for Various Infections. September 2021. IDWeek 2021 Virtual Meeting.
16. **Rebold N**, Alosaimy S, Lagnf AM, Ansari I, Belza AC, Cheaney L, Hussain H, Herbin S, Morrisette T, Abdul-Mutakabbir J, Carron C, Holger D, Claes KC, Davis SL, Ramesh M, Mckinnon JE, Sandhu A, Chopra T, Rybak MJ. Evaluation of positive blood cultures on patient outcomes with COVID-19. July 2021. 31<sup>st</sup> European Congress of Clinical Microbiology & Infectious Diseases Virtual Meeting.
17. Holger D, Lagnf AM, Belza AC, Alosaimy S, **Rebold N**, Morrisette T, Veve MP, Rybak MJ. Combination antimicrobial therapy vs. monotherapy for multidrug-resistant *Pseudomonas aeruginosa* lower respiratory tract infections. July 2021. 31<sup>st</sup> European Congress of Clinical Microbiology & Infectious Diseases Virtual Meeting.
18. Alosaimy S, Bouchard J, Kang-Birken L, Molina K, [...] **Rebold N**, et al. Real-World, Multicenter with Experience with Eravacycline for Complicated Infections July 2021. 31<sup>st</sup> European Congress of Clinical Microbiology & Infectious Diseases Virtual Meeting.
19. **Rebold N**, Alosaimy S, Lagnf A, Pearson J, Holger D, et al. Evaluation of patient characteristics and outcomes of patients treated with dalbavancin for bloodstream infections. June 2021. World Microbe Forum.
20. **Rebold N**, Lagnf AM, Belza AC, Alosaimy S, Morrisette T, Rybak MJ. Oral trimethoprim/sulfamethoxazole versus linezolid step-down therapy for methicillin-resistant *Staphylococcus aureus* bloodstream infections. May 2021. 23<sup>rd</sup> Annual Making a Difference in Infectious Diseases (MAD-ID) Meeting.

21. Holger D, Lagnf AM, Belza AC, Alosaimy S, **Rebold N**, Morrisette T, Veve MP, Rybak MJ. Extensively drug-resistant *Pseudomonas aeruginosa* lower respiratory infections: Prevalence and risk factors. May 2021. 23rd Annual Making a Difference in Infectious Diseases (MAD-ID) Meeting.
22. Alosaimy S, [...] **Rebold N**, et al. Evaluation of the Clinical Outcomes and Safety of Eravacycline in Patients Treated for *Acinetobacter baumannii*. May 2021. 23rd Annual Making a Difference in Infectious Diseases (MAD-ID) Meeting.

### National Competitions

- Rebold N, Jia L, Qiu K, Rozycki S. “A Stroke of Bad Luck: A Gold Star Solutions Proposal” April 2015
- Platform presentation. Clarion Interprofessional Healthcare Competition.

### **LEADERSHIP**

Vice-Chair – Policy & Government Affairs Committee – SIDP	January 2026 – Present
Faculty Senate - Academic and Health Affairs Committee – Howard University	August 2025 – Present
Faculty Senate - Library Systems Committee – Howard University	August 2025 – Present
Chair – Curriculum Committee – Howard University College of Pharmacy	August 2025 – Present
Co-Chair – Curriculum Committee – Howard University College of Pharmacy	September 2023 – 2025
Program Coordinator – Mid-Atlantic AIDS Education and Training Center	November 2022 – Present
Co-Chair – Antimicrobial Stewardship Committee – Howard University Hospital	August 2025 – Present
Chair – Antimicrobial Stewardship Committee – Howard University Hospital	August 2022 – 2025
Member – Curriculum Committee – Howard University College of Pharmacy	August 2022 – Present
Member – Research Committee – ACCP ID PRN	December 2021 – 2023
Member – Policy and Government Affairs Committee – SIDP	December 2020 – Present
Chair – MAD-ID Vancomycin Task Force	October 2020 – Present
<ul style="list-style-type: none"> <li>• <a href="http://Mad-id.org/vancomycin">Mad-id.org/vancomycin</a></li> </ul>	
Resident Co-Chair – Scholarship Committee – Boston Medical Center	July 2018 – July 2020
Phi Delta Chi (PDC) – VCU School of Pharmacy	March 2016 – April 2017
<ul style="list-style-type: none"> <li>• Worthy Master-at-Arms, Social Committee Chair</li> </ul>	
APhA-ASP – VCU School of Pharmacy	March 2015 – March 2017
<ul style="list-style-type: none"> <li>• President and President-elect of school chapter, Chair of the Professionalism committee</li> </ul>	

### **CERTIFICATIONS**

Georgetown-Howard Uni. Center for Clinical / Translational Science – Grant Workshop	November 2022
Planning & Writing Successful NIH Grant Proposals Workshop	November 2021
HIV Pharmacist – American Academy of HIV Medicine	April 2021, 2023
Board Certified Infectious Diseases Pharmacist (BCIDP)	November 2020
Institute for Healthcare Improvement: Basic Certificate in Quality & Safety	June 2019
ASHP Teaching Certificate for Pharmacists	June 2019
Advanced Cardiac Life Support Provider – American Heart Association	July 2018 – 2020
REVIVE! Naloxone Trainer Certification	2017
Basic Life Support Provider – American Heart Association	2015 – 2024
APhA Pharmacy-Based Immunization Delivery Certificate Program	2015 – 2024

### **LICENSURE**

Registered Pharmacist – DC Board of Pharmacy	August 2022 – Present
<ul style="list-style-type: none"> <li>• License #: PH200004583</li> </ul>	
Registered Pharmacist – Massachusetts Board of Pharmacy	July 2018 – Present
<ul style="list-style-type: none"> <li>• License #: PH238100</li> </ul>	
Registered Pharmacist – Virginia Board of Pharmacy	June 2018 – Present
<ul style="list-style-type: none"> <li>• License #: 0202216787</li> </ul>	

## PROFESSIONAL ORGANIZATIONS

---

Mid-Atlantic AIDS Education and Training Center (MAAETC)	November 2022 – Present
American Association of Colleges of Pharmacy (AACCP)	October 2022 – Present
American Society of Microbiology (ASM)	April 2021 – Present
Making A Difference in Infectious Diseases (MAD-ID)	October 2020 – Present
Society of Infectious Disease Pharmacists (SIDP)	December 2019 – Present
American College of Clinical Pharmacy (ACCP) & ID PRN (Specialty)	November 2019 – Present
European Society of Clinical Microbiology and Infectious Diseases	November 2019 – Present
American Pharmacists Association (APhA) / APhA-ASP	October 2014 – Present
American Heart Association (AHA)	August 2021 – August 2022
Massachusetts Society of Health-System Pharmacists	June 2018 – July 2020
American Society of Health-System Pharmacists (ASHP)	September 2016 – October 2019
Phi Delta Chi (PDC)	March 2015 – June 2018

## HONORS AND AWARDS

---

ACCP <i>Pharmacotherapy</i> Outstanding Reviewer	October 2024
MAD-ID 2022 Award Platform Presentation	May 2022
Distinguished Trainee Award (Fellow) – ACCP ID-PRN	October 2021
IDWeek Trainee Award	July 2021
VCU SOP - Interprofessional Practice and Collaborative Care Excellence Award	May 2018
Senior Recognition Certificate – APhA-ASP	April 2018
Harry & Zachia Shaia Foundation Pharmacy Scholarship	February 2016, 2017, 2018
Scholastic Recognition Award – Lambda Chapter, Rho Chi	November 2015
Recognition in Leadership – Beta Nu Chapter, Phi Lambda Sigma	November 2015

## COMMUNITY SERVICE

---

RAM – Remote Area Medical – Wise, Virginia	July 2017
Students Educating About Medication Management (STEAMM)	May 2016 – March 2017
Healing Eagle Clinic – Mattaponi Reservation Circle	August 2016, October 2016
(HIP HOP)	April 2015, May 2016
• Health Interventions by Student Professionals for Homeless Persons – Healing Place	
CARITAS – Congregations Around Richmond Involved To Assure Shelter	January 2016
Center for High Blood Pressure/Center for Healthy Hearts	November 2015, September 2016